M
Maravai Lifesciences Holdings Inc (MRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$7.40
-0.14 (-1.86%)
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:06 AM ET
Maravai Lifesciences Holdings Inc (MRVI) Valuation Multiples
Maravai Lifesciences Holdings (MRVI) trades at 5.2x sales and 5.6x book value. Its P/S of 5.2x is above its 5-year median of 2.8x. Its forward P/E is 370.4x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 370.4x |
| Price to sales | 5.2x |
| Price to book | 5.6x |
| PEG | N/A |
| FCF yield | -1.1% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 5.2x | 2.8x | N/A |
| P/B | 5.6x | 2.8x | N/A |
Valuation History
Over the 6 year ends shown, its P/S ranged from 2.1x in 2022 to 9.5x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $3.25 | N/A | 2.5x | 2.2x |
| 2024 | $5.45 | N/A | 2.9x | 2.3x |
| 2023 | $6.55 | N/A | 3.0x | 2.1x |
| 2022 | $14.31 | 8.0x | 2.1x | 3.5x |
| 2021 | $41.90 | 41.9x | 5.9x | 16.2x |
| 2020 | $28.05 | N/A | 9.5x | 36.2x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRVI
What is MRVI's forward P/E ratio?
Maravai Lifesciences Holdings has a forward P/E ratio of 370.4x.
Is MRVI stock overvalued?
GNG's valuation label for MRVI is Overvalued.
What is MRVI's price to sales ratio?
Maravai Lifesciences Holdings has a price to sales ratio of 5.2x.
MRVI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors